FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
COLUMBIA, Md., Sept. 13, 2016 -- Digital health technology leader WellDoc announced today it has entered a commercial partnership agreement with LifeScan Inc., one of the Johnson & Johnson Diabetes Care Companies (JJDCC) and a world leader in blood glucose monitoring, to deliver across the United States a best-in-class digital health solution for Type 2 diabetes. The companies will integrate WellDoc’s clinically validated BlueStar® diabetes management platform and mobile application, which is the first digital therapeutic approved by the U.S. Food and Drug Administration for adults who live with Type 2 diabetes, with LifeScan’s OneTouch Verio Flex™ blood glucose monitoring system with built-in Bluetooth® Smart Technology and the OneTouch Reveal digital system. The combined offering will seek to create a comprehensive, data-driven and payer-reimbursed program for Type 2 diabetes management.
“We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson Innovation – JJDC, Inc. investment in WellDoc. Together, WellDoc and LifeScan will provide those living with Type 2 diabetes a best-in-class diabetes management solution with robust data analytics powered by BlueStar’s patented clinical and behavioral engine,” said Kevin McRaith, CEO of WellDoc. “We will facilitate national adoption of this innovative first-in-class digital health solution. Our goal is to help make a difference in the lives of millions of Americans living with this chronic disease while bringing the U.S. healthcare system cost-savings opportunities.”
WellDoc’s BlueStar® digital therapeutic platform guides patients living with Type 2 diabetes with lifestyle and behavioral support to self-manage this challenging condition, while also assisting healthcare teams in making timely clinical decisions. With BlueStar, patients enter specific information, such as their blood glucose levels and carbohydrate intake, as well as have their health and wellness data synchronized from wearables. Through the application, they then receive customized guidance, messages, educational tips, and motivation – in real time (whether their phone or tablet is connected to Wi-Fi or not). The combination of patient self-management and clinical decision support can contribute to positive clinical outcomes and significant cost savings for the U.S. healthcare system.
WellDoc is the first digital health company built on a life sciences business model. The Company has published articles in peer reviewed journals highlighting improvement in clinical outcomes and enhanced patient engagement. Similar findings in real-world clinical settings could translate into significant cost-savings for the healthcare system.
In addition to this innovative partnership with LifeScan, WellDoc also has important collaborations with other leading healthcare and technology companies, such as Samsung Electronics Co. Ltd, the Ontario Telemedicine Network, and Human API.
About WellDoc®
WellDoc is a digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc has commercialized BlueStar®, a digital therapeutic, for adults with type 2 diabetes. This therapeutic is designed to fill the support gap between patients and providers during the 8700 hours that individuals live their lives outside the healthcare system each year. WellDoc has a proven track record of contributing published, peer-reviewed clinical evidence since 2008 and presented real-world patient engagement and clinical outcomes at the American Diabetes Association’s (ADA) 76th Scientific Sessions. BlueStar® is recognized by the ADA on its website as the first and only in the new class of diabetes treatment known as Mobile Prescription Therapy. In a recently published Forbes blog, WellDoc was named among one of five healthcare tech companies to watch in 2016. For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.
Media Contact: Juliette Bogus PressComm PR Tel: +410.980.5687 Email: [email protected]
